期刊文献+

可溶性血管内皮生长因子受体1与胎盘生长因子的比值预测子痫前期的价值 被引量:4

Value of a ratio of sFlt-1 to PLGF in prospecting the preeclampsia
原文传递
导出
摘要 目的探讨血清可溶性血管内皮生长因子受体1(sFlt-1)联合胎盘生长因子(PLGF)预测孕妇子痫前期的敏感性和特异性。方法用ELISA检测352例子痫前期孕妇在孕16-20周时血清sFlt-1和PLGF水平。其中,子痫前期高风险因素(A组)122例,正常妊娠(B组)230例。结果A组血清sFlt-1浓度为(308.5±85.5)ng/L,明显高于B组的(265.3±98.6)ng/L(P<0.01),血清PLGF浓度为(30.8±9.0)ng/L,与B组的(30.4±11.6)ng/L相仿(P>0.05)。A组sFlt-1/PLGF比值与体重指数呈正相关(r=0.724,P<0.01);当sFlt-1/PLGF比值>11.0时,预测子痫前期的敏感性为84.0%,特异性97.9%;而B组敏感性为59.1%,特异性为97.1%。结论孕16-20周,血清sFlt-1/PLGF比值在子痫前期高风险因素孕妇预测子痫前期效果优于正常妊娠孕妇。 Objective To study the sensitivity and specificity of the ratio of soluble fms-like tyrosine kinase-1(sFlt-1) to placenta growth factor(PLGF) for predicating the development of preeclampsia.Methods Serum levels of sFlt-1 and PLGF were detected by ELISA in 122 women with high risk for preeclampsia(group A) and 230 normal pregnant women(group B),who were in 16 to 20 weeks of pregnancy.The ratio of sFlt-1 to PLGF was calculated.Results Serum sFlt-1 in group A was(308.5±85.5) ng/L,which was higher than(265.3±98.6) ng/L in group B(P0.01).The PLGF level of group A was similar to that of group B [(30.8±9.0) ng/L vs.(30.4±11.6) ng/L](P0.05).The ratio of sFlt-1 to PLGF in group A was positively correlated to body mass index(BMI)(r=0.724,P0.01).When the ratio was 11.0 in 16 to 20 weeks of pregnancy,the sensitivity and specificity in predicating the development of preeclampsia in group A were 97.9% and 97.1%,respectively,which were 84.0% and 59.1% in group B.Conclusion The ratio of sFlt-1 to PLGF as an early marker for predicating development of preeclampsia is more valuable in the pregnant women with high risk for preeclampsia than in those with normal pregnancy.
出处 《江苏医药》 CAS 北大核心 2013年第14期1641-1643,共3页 Jiangsu Medical Journal
基金 常州市卫生局规划项目(WZ201028)
关键词 可溶性血管内皮生长因子受体1 胎盘生长因子 子痫前期 Soluble fms-like tyrosine kinase-1 Placenta growth factor Preeclampsia
作者简介 通讯作者:张一呜E-mail:zhangym88108181@163.COm
  • 相关文献

参考文献9

  • 1Goldenberg RL,Culhane JF,Iams JD,et al.Epidemiology andcauses of preterm birth[J].Lancet,2008,371(9606):75-84.
  • 2Levine RJ,Maynard SE,Qian C,et al.Circulating angiogenicfactors and the risk of preeclampsia[J].N Engl J Med,2004,350(7):672-683.
  • 3张一鸣,袁小松,蒋丽霞,蒋雅琴.子痫前期患者血清胎盘生长因子及可溶性血管内皮生长因子受体1表达及意义[J].江苏医药,2010,36(22):2639-2642. 被引量:3
  • 4袁小松,张一鸣,蒋丽霞,魏梓雯.血清血管生成因子预测子痫前期患病风险的价值[J].江苏医药,2012,38(1):40-42. 被引量:4
  • 5乐杰,谢幸,等主编.妇产科学[M].第7版.北京:人民卫生出版社,2009.241.
  • 6Levine RJ,Lam C,Qian C,et al.Soluble endoglin and othercirculating antiangiogenic factors in preeclampsia[J].N Engl JMed,2006,350(10):992-1005.
  • 7Anderson UD,Olsson MG,Kristensen KH,et al.Review:biochemical markers to predict preeclampsia[J].Placenta,2012,33(Suppl):S42-S47.
  • 8Verlohren S,Herraiz I,Lapaire O,et al.The sFlt-1/PlGF ratioin different types of hypertensive pregnancy disorders and itsprognostic potential in preeclamptic patients[J].Am J ObstetGynecol,2012,206(58):e1-e8.
  • 9Benton SJ,Hu Y,Xie F,et al.Angiogenic factors as diagnostictests for preeclampsia:aperformance comparison between twocommercial immunoassays[J].Am J Obstet Gynecol,2011,205(469):e1-e8.

二级参考文献17

  • 1叶元华,刘玲,詹瑛,彭伟.可溶性血管内皮生长因子受体1在子痫前期患者胎盘组织中的表达及意义[J].中华妇产科杂志,2006,41(8):521-524. 被引量:7
  • 2乐杰,谢幸,等主编.妇产科学[M].第7版.北京:人民卫生出版社,2009.241.
  • 3乐杰主编.妇产科学[M].第7版.北京:人民卫生出版社,2009.271-272.
  • 4Sibai B,Dekker G,Kupferminc M. Pre-eelampsia[J]. Lancet, 2005,94(61) : 785-799.
  • 5Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia[J]. N Engl J Med,2004, 350(7) : 672-683.
  • 6Huppertz B. The feto-maternal interface: setting the stage for potential immune interactions[J]. Semin Immunopathol,2007, 29(2) :83- 94.
  • 7Soleymanlou N,Jurisica I, Nevo O, et al. Molecular evidence of placental hypoxia in preeclampsia [J]. J Clin Endocrinol Metab, 2005,90 (7) : 4299-4308.
  • 8Redman CW, Sargent IL. Latest advances in understanding preeciampsia[J]. Science,2005,308(5728) : 1592-1594.
  • 9Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-i) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate[J]. J Matern Fetal Neonatal Med, 2008,21 (1) : 9-23.
  • 10Zhou Y, MeMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survivalare dysregulated in severe preeclampsia and hemolysis, elevated liver and low platelets syndrome[J]. Am J Pathoh 2002,160(4) :1405-1423.

共引文献194

同被引文献17

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部